HIGHLIGHTS
- who: Xiangyang Zhang from the Zhengzhou University, Zhengzhou, Henan, People’s Republic China have published the paper: Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer, in the Journal: (JOURNAL)
- what: All the experiments were repeated more than three times, and the obtained data were expressed as mean ± s.e.m.
- how: The cell viability results indicated that the 510K cells developed a stronger drug resistance than 510 cells (Fig 1A B). The results showed that the encapsulation efficiency of Adriamycin reached 95% and the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.